Short description
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.
Description
Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates the response to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada.
Last funding
Cannot Access
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Montréal, Quebec, Canada, North America
Founded on
January 1, 2002
Non-profit?
No
Acquired?
No
Employees count
11-50
Investors
No Way, Nopepepe, Noaccessforu, Noway Youcantaccess, Blurry Noaccess, Noaccess
Sign in for full access
Founders
Mario Filion